PR Newswire Clinical TrialsOriginal article
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
Phase 1ATG-201Positive
AI Analysis
Summary
Antengene received clinical trial approval in Australia for the Phase 1 ATTRACT study of ATG-201, a CD19 x CD3 bispecific T cell engager, for the treatment of B cell-related autoimmune diseases.
Clinical Trial Data
Phase
Phase 1
Outcome Details
Clinical trial approval received in Australia
Importance:5/10
Sentiment:
0.70
clinical trial approvalPhase 1AustraliaCD19 x CD3 TCEautoimmune disease
Read the original article
Published by PR Newswire Clinical Trials on August 25, 2026 12:30 AM